Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601402 | 1.00 | CAPN1 (0.39) | CAPN1GHSRZAP70SRCMAOB | |
| SCHEMBL8579396 | 0.91 | SMN1; SMN2 (0.41) | CAPN1GHSRZAP70SRCMAOB | |
| SCHEMBL4284133 | 0.89 | MAOB (0.37) | CAPN1GHSRZAP70SRCMAOB | |
| SCHEMBL6600950 | 0.89 | CAPN1 (0.37) | CAPN1GHSRZAP70SRCMAOB | |
| SCHEMBL6601217 | 0.85 | PSMB5 (0.36) | GHSRMAOBFCER2PSMB5MMP9 | |
| SCHEMBL6601730 | 0.85 | ZAP70 (0.34) | CAPN1GHSRZAP70SRCFCER2 | |
| SCHEMBL4282449 | 0.85 | ZAP70 (0.39) | CAPN1GHSRZAP70SRCMAOB | |
| SCHEMBL6602122 | 0.84 | MC4R (0.42) | GHSRZAP70SRCMAOBFCER2 | |
| SCHEMBL6606297 | 0.82 | PSMB5 (0.37) | GHSRMAOBTACR1PSMB5MMP9 | |
| SCHEMBL6602371 | 0.81 | MC4R (0.40) | GHSRZAP70SRCTACR1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | NOVO NORDISK A/S (DK) | 2009-06-11 | — | — | US | claimed |
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | NOVO NORDISK A/S (DK) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | GIPR, GHSR, GPR119 | CAPN1 3835/4885GHSR 2/4885ZAP70 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.